Xiaoyi Guo

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma.

First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma.

Journal: Molecular pharmaceutics
Published: July 07, 2026

A Prospective Head-to-Head Comparison of HER2-Targeted and 18 F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.

A Prospective Head-to-Head Comparison of HER2-Targeted and 18 F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.

Journal: Clinical nuclear medicine
Published: January 03, 2026

Al18F-NOTA-HER2-BCH PET/MR for regional lymph node metastasis assessment in HER2-low and -positive breast cancer: a prospective study.

Al18F-NOTA-HER2-BCH PET/MR for regional lymph node metastasis assessment in HER2-low and -positive breast cancer: a prospective study.

Journal: European journal of nuclear medicine and molecular imaging
Published: December 17, 2025

Folate Receptor Alpha Targeted Immuno-Positron Emission Tomography Probe for Noninvasive Imaging in Triple-Negative Breast Cancer.

Folate Receptor Alpha Targeted Immuno-Positron Emission Tomography Probe for Noninvasive Imaging in Triple-Negative Breast Cancer.

Journal: Chemical & biomedical imaging
Published: August 14, 2025

Clinical impact of [68Ga]Ga-RM2 positron emission tomography imaging on staging and prognosis in estrogen receptor-positive breast cancer: A pilot study.

Clinical impact of [68Ga]Ga-RM2 positron emission tomography imaging on staging and prognosis in estrogen receptor-positive breast cancer: A pilot study.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: July 21, 2025

Al 18 F-NOTA-HER2-BCH Versus 18 F-FDG PET/CT for Detecting Bone Metastases : Sensitivity and Quantitative Comparison.

Al 18 F-NOTA-HER2-BCH Versus 18 F-FDG PET/CT for Detecting Bone Metastases : Sensitivity and Quantitative Comparison.

Journal: Clinical nuclear medicine
Published: July 21, 2025

Hypoxia Inducible Factor-1α Specific Probe for Tumor Hypoxia Positron Emission Tomography Imaging.

Hypoxia Inducible Factor-1α Specific Probe for Tumor Hypoxia Positron Emission Tomography Imaging.

Journal: Journal of labelled compounds & radiopharmaceuticals
Published: May 26, 2025

Diagnostic value of 18F-FDG PET/CT in the follow-up of conjunctival melanoma.

Diagnostic value of 18F-FDG PET/CT in the follow-up of conjunctival melanoma.

Journal: Annals of nuclear medicine
Published: April 19, 2025

Diagnostic value of 18F-FDG PET/CT in the follow-up of metastatic uveal melanoma.

Diagnostic value of 18F-FDG PET/CT in the follow-up of metastatic uveal melanoma.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: February 16, 2025

Inhibition of colorectal cancer cell growth by downregulation of M2-PK and reduction of aerobic glycolysis by clove active ingredients.

Inhibition of colorectal cancer cell growth by downregulation of M2-PK and reduction of aerobic glycolysis by clove active ingredients.

Journal: Frontiers in pharmacology
Published: December 28, 2024

Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients.

Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients.

Journal: European journal of nuclear medicine and molecular imaging
Published: November 28, 2024

Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma.

Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma.

Journal: Molecular pharmaceutics
Published: July 30, 2024
Showing 1-12 of 42

Last Updated: 09/26/2026